<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02689271</url>
  </required_header>
  <id_info>
    <org_study_id>15/0692</org_study_id>
    <nct_id>NCT02689271</nct_id>
  </id_info>
  <brief_title>CombIning advaNces in imagiNg With biOmarkers for improVed Diagnosis of Aggressive prosTate cancEr</brief_title>
  <acronym>INNOVATE</acronym>
  <official_title>CombIning advaNces in imagiNg With biOmarkers for improVed Diagnosis of Aggressive prosTate cancEr</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To enable the paradigm of mp-MRI before biopsy in all patients with suspected prostate cancer&#xD;
      by better selecting patients who will benefit from diagnostic MRI and by improving the&#xD;
      performance of the mp-MRI itself&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will undergo an advanced diffusion-weighted MRI sequence called VERDICT with the&#xD;
      intention of better characterising prostate cancer. A panel of serum and urine biomarkers&#xD;
      will also be analysed, which we hope will predict those patients who go on have a positive&#xD;
      MRI.&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
        -  To establish a fluidic marker - prostate MRI paradigm which: (i) utilises fluidic&#xD;
           markers to rationalise selection of patients with significant prostate cancer; and (ii)&#xD;
           improves the diagnostic accuracy of imaging over and above standard multiparametric (mp)&#xD;
           MRI&#xD;
&#xD;
        -  Enable a pathway for rapid clinical evaluation of emerging fluidic markers and exosomes&#xD;
&#xD;
        -  Assess the repeatability of VERDICT MRI&#xD;
&#xD;
        -  Ascertain whether VERDICT derived quantitative parameters correlate with quantitative&#xD;
           histological parameters&#xD;
&#xD;
        -  Develop a database of fluidic marker and VERDICT characterised, mp-MRI, histologically&#xD;
           validated patients for subsequent exploratory and longitudinal outcome analysis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy of VERDICT MRI</measure>
    <time_frame>3 - 6 months (after targeted biopsy or follow up MRI)</time_frame>
    <description>Radiological assessment with added VERDICT MRI improves the specificity of mp-MRI for detection of significant prostate cancer by &gt;10% above standard multi-parametric MRI alone.</description>
  </primary_outcome>
  <enrollment type="Actual">365</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>VERDICT diffusion-weighted microstructure imaging sequence</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men with suspected prostate cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men referred to University College London Hospital (UCLH) for prostate mp-MRI&#xD;
             following biopsy elsewhere and biopsy naive men presenting to UCLH with a clinical&#xD;
             suspicion of prostate cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Men unable to have a MRI scan, or in whom artefact would reduce quality of MRI&#xD;
&#xD;
          -  Men unable to given informed consent&#xD;
&#xD;
          -  Previous treatment (prostatectomy, radiotherapy, brachytherapy) of prostate cancer&#xD;
&#xD;
          -  On-going hormonal treatment for prostate cancer&#xD;
&#xD;
          -  Previous biopsy within 6 months of scheduled mp-MRI&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>Camden</city>
        <zip>NW12BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Fluidics</keyword>
  <keyword>Diffusion MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

